All In Biotech

Drug Trial Radar · NCT00289783

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

A Phase III, Randomized, Multinational Study, Double-blinded for the Immunogenicity and Consistency Evaluation of 3 Hib-MenCY-TT Vaccine Lots and Single-blinded and Controlled for the Evaluation of Safety and Immunogenicity of GSK Biologicals' Haemophilus Influenzae Type b and Neisseria Meningitidis Serogroups C and Y-tetanus Toxoid Conjugate Vaccine Combined (Hib-MenCY-TT) Compared to Monovalent Hib Vaccine in Healthy Infants at 2, 4, 6, and 12 to 15 Months of Age.

Last checked: Nov 20, 2026Latest source record: Aug 24, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 4,441 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

4,441

Actual

Start

Feb 22, 2006

Primary completion

Aug 27, 2007

Study completion Feb 26, 2008

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Feb 10, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Prevention
Who can join
All sexes, from 6 weeks, up to 15 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study evaluates the immunogenicity and consistency of 3 Hib-MenCY-TT vaccine lots and the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with Pediarix® to healthy infants at 2, 4, and 6 months of age. The study will also evaluate the safety and immunogenicity of Hib-MenCY-TT vaccine compared to a control group receiving licensed Hib conjugate vaccine, when each are co-administered with M-M-R® II and Varivax® at 12 to 15 months of age.

Conditions

  • Haemophilus Influenzae Type b
  • Neisseria Meningitidis

Interventions

  • GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccineBiological

    3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.

  • ActHIBBiological

    3-dose intramuscular injection at 2, 4 and 6 months of age.

  • PedvaxHIBBiological

    1 booster dose by intramuscular injection at 12 to 15 months of age.

  • PediarixBiological

    3-dose intramuscular injection at 2, 4 and 6 months of age.

  • PrevnarBiological

    3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.

  • M-M-R IIBiological

    1 booster dose by subcutaneous injection at 12 to 15 months of age.

  • VarivaxBiological

    1 booster dose by subcutaneous injection at 12 to 15 months of age

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Anti-Polyribosyl Ribitol Phosphate (PRP) Antibody ConcentrationsTime frame: One month after primary vaccination
  2. Neisseria Meningitidis Serogroup C (MenC) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody TitersTime frame: One month after primary vaccination
  3. Neisseria Meningitidis Serogroup Y (MenY) Serum Bactericidal Assay Using Human Complement (hSBA) Antibody TitersTime frame: One month after primary vaccination
  4. hSBA-MenC Antibody TitersTime frame: Prior to the fourth dose vaccination and 42 days after the fourth dose
  5. hSBA-MenY Antibody TitersTime frame: Prior to the fourth dose vaccination and 42 days after the fourth dose
  6. Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per Milliliter (µg/mL)Time frame: One month after primary vaccination
  7. Number of Subjects With hSBA-MenC Titer Equal to or Above 1:8Time frame: 42 days after the fourth dose
  8. Number of Subjects With hSBA-MenY Titer Equal to or Above 1:8Time frame: 42 days after the fourth dose
  9. Number of Subjects With Anti-measles Antibody Concentrations Equal to or Above 150 Milli-international Units Per Milli-liter (mIU/ML)Time frame: 42 days after the fourth dose
  10. Number of Subjects With Anti-PRP Antibody Concentration Equal to or Above 1.0 Microgram Per MilliliterTime frame: 42 days after the fourth dose
  11. Number of Subjects With Anti-mumps Titer Equal to or Above 28 Estimated Dose 50 (ED50)Time frame: 42 days after the fourth dose
  12. Number of Subjects With Anti-rubella Antibody Concentrations Equal to or Above 10 International Units Per Milli-litre (IU/mL)Time frame: 42 days after the fourth dose
  13. Number of Subjects With Anti-varicella Titer Equal to or Above 1:5Time frame: 42 days after the fourth dose

Locations

93 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Birmingham, Alabama

  • GSK Investigational Site

    Phoenix, Arizona

  • GSK Investigational Site

    Bryant, Arkansas

  • GSK Investigational Site

    Fayetteville, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    Little Rock, Arkansas

  • GSK Investigational Site

    East Artesia, California

  • GSK Investigational Site

    Fountain Valley, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    Fresno, California

  • GSK Investigational Site

    La Jolla, California

  • GSK Investigational Site

    Oakland, California

  • GSK Investigational Site

    Paramount, California

  • GSK Investigational Site

    Rolling Hills Estates, California

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    West Covina, California

  • GSK Investigational Site

    Longmont, Colorado

  • GSK Investigational Site

    Norwich, Connecticut

  • GSK Investigational Site

    Cocoa Beach, Florida

  • GSK Investigational Site

    Melbourne, Florida

  • GSK Investigational Site

    Pembroke Pines, Florida

  • GSK Investigational Site

    Rockledge, Florida

  • GSK Investigational Site

    Nampa, Idaho

  • GSK Investigational Site

    Des Moines, Iowa

  • GSK Investigational Site

    Des Moines, Iowa

  • GSK Investigational Site

    Arkansas City, Kansas

  • GSK Investigational Site

    Kansas City, Kansas

  • GSK Investigational Site

    Bardstown, Kentucky

  • GSK Investigational Site

    Lexington, Kentucky

  • GSK Investigational Site

    Louisville, Kentucky

  • GSK Investigational Site

    Bossier City, Louisiana

  • GSK Investigational Site

    Baltimore, Maryland

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Fall River, Massachusetts

  • GSK Investigational Site

    Jamaica Plain, Massachusetts

  • GSK Investigational Site

    Kalamazoo, Michigan

  • GSK Investigational Site

    Portage, Michigan

  • GSK Investigational Site

    Stevensville, Michigan

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.